Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part

Single dose administered subcutaneously (under the skin) as a comparator at all dose levels

Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.

Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels

Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part

Single dose administered intravenously (into a vein), as a comparator at all dose levels